您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > Semaglutide(acetate)
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Semaglutide(acetate)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Semaglutide(acetate)图片
包装与价格：
包装价格(元)
1mg电议
5mg电议
10mg电议
25mg电议

产品介绍
A GLP-1R agonist
Canonical SMILESO=C(C(C)(C)NC([C@H](CC1=CNC=N1)N[H])=O)N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@H](O)C)([H])C(N[C@H](C(N[C@]([C@H](O)C)([H])C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(O)C=C2)C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@](C(N[C@H](C(N[C@@H](CC3=CNC4=C3C=CC=C4)C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)=O)CC(C)C)=O)=O)C)=O)([H])[C@@H](C)CC)=O)CC5=CC=CC=C5)=O)=O)=O)C)=O)C)=O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)CC6=CC=CC=C6)=O)=O)=O.CC(O)=O
分子式C187H291N45O59.XC2H4O2
分子量4113.6
溶解度DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:4): 0.2 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Semaglutide is an agonist of glucagon-like peptide 1 receptor (GLP-1R; EC50= 6.2 pM in a reporter assay using BHK cells expressing the human receptor).1It decreases blood glucose levels in thedb/dbmouse model of type 2 diabetes (ED50=<2 nmolkg). semaglutide (25 kg)prevents decreases in the number of dopaminergic neurons substantia nigra and increases lipid peroxidation striatum, as well improves motor coordination rotarod footprint tests a mouse model parkinson's disease induced by mptp.2It decreases neuronal loss in the hippocampal dentate gyrus and CA1 and CA3 regions and improves motor coordination and grip strength in the beam-walking and hanging wire tests, respectively, in a rat model of stroke induced by permanent middle cerebral artery occlusion (MCAO) when administered at a dose of 10 nmol/kg every other day.3Formulations containing semaglutide have been used in the treatment of type 2 diabetes.

1.Lau, J., Bloch, P., SchÄffer, L., et al.Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutideJ. Med. Chem.58(18)7370-7380(2015) 2.Zhang, L., Zhang, L., Li, L., et al.Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse modelNeuropeptides7170-80(2018) 3.Yang, X., Feng, P., Zhang, X., et al.The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of strokeNeuropharmacology158:107748(2019)